Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Common Shares Outstanding
Adaptimmune Therapeutics PLC
Common Shares Outstanding Peer Comparison
Competitive Common Shares Outstanding Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Common Shares Outstanding
$1.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Common Shares Outstanding
$98.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Common Shares Outstanding
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Common Shares Outstanding
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Common Shares Outstanding
£49.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Common Shares Outstanding
£66m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
See Also
What is Adaptimmune Therapeutics PLC's Common Shares Outstanding?
Common Shares Outstanding
1.5B
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Common Shares Outstanding amounts to 1.5B USD.
What is Adaptimmune Therapeutics PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
20%
Over the last year, the Common Shares Outstanding growth was 54%. The average annual Common Shares Outstanding growth rates for Adaptimmune Therapeutics PLC have been 18% over the past three years , 20% over the past five years .